Alnylam (NASDAQ: ALNY) is a U.S.-based biopharma company primarily developing RNA interference drugs. The company recently announced that the USFDA has approved its drug Givlaari, which has proven effective in silencing the gene behind the rare metabolic disease acute hepatic porphyrias. This drug was approved 3 months ahead of schedule and only 16 months after the drug was first filed, boosting the outlook for the firm’s revenues and profits. Notably, the company currently only has one commercial drug in the market – Onpattro. Givlaari will soon be the second one. The company’s improved prospects after Givlaari’s approval drove the rally in Alnylam’s stock.

We step back from these recent swings to review Alnylam’s performance over the last few years, as a context for what might come next. Our Interactive dashboard – Exploring The Reason Behind The 25% Jump in Alnylam’s Stock In A Fortnight, reviews the near term reasons and the big picture.

The context for the last few years:

A closer look At Alnylam’s Total Revenues over the last few years and the outlook.

Total Revenues for Alnylam substantially decreased from $89.9 Mil in 2017 to $74.9 Mil in 2018; a decline by 16.7%. (On account of lower R&D collaboration revenue)

This compares with Total Revenues growth of:

We expect Total Revenues growth to be 194.3% in 2019 thanks to the expected launch of the new drug as well as from ramping up of existing customers

A closer look At Alnylam’s Total Expenses over the last few years and the outlook.

Total Expense for Alnylam substantially increased from $580 Mil in 2017 to $836 Mil in 2018; an increase of 44%. (On account of higher R&D cost on its own pipeline as well as higher launch costs)

This compares with Total Expense growth of 27% in 2017. We expect Total Expense growth to be 29.5% in 2019.

 

How does Alnylam’s Revenue Growth compare with rivals?

For more information on how Alnylam’s revenue growth compares with Ionis Pharmaceuticals, Bluebird bio and BioMarin Pharmaceutical, view our interactive dashboard analysis.

 

How has Alnylam’s LBT trended?

LBT for Alnylam increased substantially by 55.1% from $491 Mil in 2017 to $761.5 Mil in 2018.

We expect LBT to increase by 13.3% to $863 Mil in 2019.

 

How has Alnylam’s Net Income and EPS trended?

For more details about Alnylam’s Net Income and EPS, view our interactive dashboard analysis.

 

What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance TeamsProduct, R&D, and Marketing Teams More Trefis Data Like our charts? Explore example interactive dashboards and create your own